June 2022
Volume 63, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2022
Use of a deep learning image quality model to evaluate impact of clinically relevant forms of degradation on the glaucoma gradability of fundus images
Author Affiliations & Notes
  • Benton Gabriel Chuter
    Hamilton Glaucoma Center, Viterbi Family Department of Ophthalmology and Shiley Eye Institute, University of California San Diego, La Jolla, California, United States
  • Justin Huynh
    Hamilton Glaucoma Center, Viterbi Family Department of Ophthalmology and Shiley Eye Institute, University of California San Diego, La Jolla, California, United States
    Department of Computer Science and Engineering, University of California San Diego, La Jolla, California, United States
  • Mark Christopher
    Hamilton Glaucoma Center, Viterbi Family Department of Ophthalmology and Shiley Eye Institute, University of California San Diego, La Jolla, California, United States
  • Christopher Bowd
    Hamilton Glaucoma Center, Viterbi Family Department of Ophthalmology and Shiley Eye Institute, University of California San Diego, La Jolla, California, United States
  • Rui Fan
    Hamilton Glaucoma Center, Viterbi Family Department of Ophthalmology and Shiley Eye Institute, University of California San Diego, La Jolla, California, United States
    College of Electronics and Information Engineering,, Tongji University, Shanghai, China
  • Michael Henry Goldbaum
    Hamilton Glaucoma Center, Viterbi Family Department of Ophthalmology and Shiley Eye Institute, University of California San Diego, La Jolla, California, United States
  • Akram Belghith
    Hamilton Glaucoma Center, Viterbi Family Department of Ophthalmology and Shiley Eye Institute, University of California San Diego, La Jolla, California, United States
  • Christopher A Girkin
    Hamilton Glaucoma Center, Viterbi Family Department of Ophthalmology and Shiley Eye Institute, University of California San Diego, La Jolla, California, United States
  • Massimo A. Fazio
    Hamilton Glaucoma Center, Viterbi Family Department of Ophthalmology and Shiley Eye Institute, University of California San Diego, La Jolla, California, United States
    Department of Biomedical Engineering, The University of Alabama at Birmingham College of Arts and Sciences, Birmingham, Alabama, United States
  • Carlos G DeMoraes
    Bernard and Shirlee Brown Glaucoma Research Laboratory, Harkness Eye Institue, Columbia University Irving Medical Center, New York, New York, United States
  • Jeffrey M Liebmann
    Bernard and Shirlee Brown Glaucoma Research Laboratory, Harkness Eye Institue, Columbia University Irving Medical Center, New York, New York, United States
  • Robert N Weinreb
    Hamilton Glaucoma Center, Viterbi Family Department of Ophthalmology and Shiley Eye Institute, University of California San Diego, La Jolla, California, United States
  • Linda M Zangwill
    Hamilton Glaucoma Center, Viterbi Family Department of Ophthalmology and Shiley Eye Institute, University of California San Diego, La Jolla, California, United States
  • Footnotes
    Commercial Relationships   Benton Chuter None; Justin Huynh None; Mark Christopher None; Christopher Bowd None; Rui Fan None; Michael Goldbaum None; Akram Belghith None; Christopher Girkin National Eye Institute, EyeSight Foundation of Alabama, Research to Prevent Blindness, Heidelberg Engineering, GmbH, Code F (Financial Support); Massimo Fazio National Eye Institute, EyeSight Foundation of Alabama, Research to Prevent Blindness, Heidelberg Engineering, GmbH, Code F (Financial Support); Carlos DeMoraes Novartis, Galimedix, Belite, Reichet, Carl Zeiss, Perfuse Therapeutics, Code C (Consultant/Contractor), Ora Clinical, Code E (Employment), Heidelberg, Topcon, Code R (Recipient); Jeffrey Liebmann Alcon, Allergan, Bausch & Lomb, Carl Zeiss Meditec, Heidelberg Engineering, Reichert, Valeant Pharmaceuticals, Code C (Consultant/Contractor), Bausch & Lomb, Carl Zeiss Meditec, Heidelberg Engineering, National Eye Institute, Novartis, Optovue, Reichert Technologies, Research to Prevent Blindness, Code F (Financial Support); Robert Weinreb Abbvie, Aerie Pharmaceuticals, Allergan, Equinox, Eyenovia, Nicox, Topcon, Code C (Consultant/Contractor), Heidelberg Engineering, Carl Zeiss Meditec, Konan Medical, Optovue, Centervue, Bausch&Lomb, Topcon; P: Toromedes, Carl Zeiss Meditec, Code F (Financial Support); Linda Zangwill Abbvie Inc. Digitial Diagnostics, Code C (Consultant/Contractor), National Eye Institute, Carl Zeiss Meditec Inc., Heidelberg Engineering GmbH, Optovue Inc., Topcon Medical Systems Inc. P: Zeiss Meditec, Code F (Financial Support)
  • Footnotes
    Support  EY11008, EY19869, EY14267, EY027510, EY026574, EY029058, P30EY022589, and participant retention incentive grants in the form of glaucoma medication at no cost from Novartis/Alcon Laboratories Inc, Allergan, Akorn, and Pfizer Inc. Unrestricted grant from Research to Prevent Blindness, New York, New York, UCSD School of Medicine Summer Research Fellowship
Investigative Ophthalmology & Visual Science June 2022, Vol.63, 2043 – A0484. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Benton Gabriel Chuter, Justin Huynh, Mark Christopher, Christopher Bowd, Rui Fan, Michael Henry Goldbaum, Akram Belghith, Christopher A Girkin, Massimo A. Fazio, Carlos G DeMoraes, Jeffrey M Liebmann, Robert N Weinreb, Linda M Zangwill; Use of a deep learning image quality model to evaluate impact of clinically relevant forms of degradation on the glaucoma gradability of fundus images. Invest. Ophthalmol. Vis. Sci. 2022;63(7):2043 – A0484.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Poor image quality can adversely affect the ability of DL algorithms to detect glaucoma. This study evaluates the effect of several common types of image degradation on a DL model that automates quality assessment of fundus photographs.

Methods : 2,815 fundus images from the Diagnostic Innovations in Glaucoma Study and African Descent and Glaucoma Evaluation Study were used to develop a DL model to automate quality assessment. This model was tested on 11,350 photographs from the Ocular Hypertension Treatment Study. Several ablative operations were separately implemented to degrade high-quality images (QS=0) into low quality ones (QS≥0.1). Gaussian blur, brightness (bias) increases and decreases, contrast enhancement factor (gain) decreases, and Gaussian-distributed additive noise were applied. In order to determine the range of degradation values, images were degraded until quality scores peaked at a maximum quality value. For each type of ablation, the maximum degree of degradation was set as the value for which the resulting quality score first surpassed 95% of this peak poor quality value. Within this range, each image was incrementally degraded to create 100 progressively ablated photographs for that ablation form.

Results : While all degradations consistently yielded poor quality scores (Figure 1), each type of ablation yielded different degradation-QS profiles. Noise was the strongest determinant of quality, followed by contrast and focus. The model was more limited in recognizing the extent of degradation for both increased and decreased brightness (max QS = 0.45 and 0.76, respectively). The model appeared especially sensitive to the Gaussian noise ablation type; random distribution variance of 0.0075 and 0.0125 proved sufficient to degrade an image to a poor quality score.

Conclusions : A DL model to assess fundus photography quality can offer insights into factors influencing DL models for detection of eye disease. Evaluation of the performance of a glaucomatous optic neuropathy model on variably degraded datasets in conjunction with grading by human experts may validate or refute these insights.

This abstract was presented at the 2022 ARVO Annual Meeting, held in Denver, CO, May 1-4, 2022, and virtually.

 

Figure 1. Degradations at key QS thresholds. 1) No degradation 2) First degradation exceeding low quality threshold 3) Peak degradation. A) Gaussian blur B) Increased brightness C) Decreased brightness D) Decreased contrast E) Increased noise.

Figure 1. Degradations at key QS thresholds. 1) No degradation 2) First degradation exceeding low quality threshold 3) Peak degradation. A) Gaussian blur B) Increased brightness C) Decreased brightness D) Decreased contrast E) Increased noise.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×